The role of the microbiota in the pathogenesis of obesity and type 2 diabetes;Die Rolle der Mikrobiota bei der Entstehung von Adipositas und Typ-2-Diabetes

Diabetologie und Stoffwechsel

Volumn 10, Issue 1, 2015, Pages R1-R12

  Simon, M C ^a,b   Mussig K ^a,b,c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Deutsches Zentrum für Diabetes Forschung DZD e V Partner Düsseldorf   (Germany)

^c Department of Orthopedic Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID;

ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; DISEASE ASSOCIATION; DYSBIOSIS; FECES MICROFLORA; HIGH RISK PATIENT; HUMAN; INTESTINE FLORA; METABOLIC SYNDROME X; MICROBIAL DIVERSITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS;

EID: 84934874571     PISSN: 18619002     EISSN: 18619010     Source Type: Journal    
DOI: 10.1055/s-0034-1399024     Document Type: Article

References (59)

1. Danaei G., Finucane M. M., Lu Y. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet: 2011; 378 31 40
2. IDF International Diabetes Federation (IDF) Diabetes Atlas. 2013; 6th ed Im Internet: http://www.idf.org/sites/default/files/EN-6E-Atlas-Full-0.pdf
3. Tilg H., Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest: 2011; 121 2126 2132
4. Tilg H., Moschen A. R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med: 2008; 14 222 231
5. Palermo A., Maggi D., Maurizi A. R. et al. Prevention of type 2 diabetes mellitus: is it feasible? Diabetes Metab Res Rev: 2014; 30 01 4 12
6. Friedman J. M. Modern science versus the stigma of obesity. Nat Med: 2004; 10 563 569
7. Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature: 2012; 489 242 249
8. Sommer F., Backhed F. The gut microbiota - masters of host development and physiology. Nat Rev Microbiol: 2013; 11 227 238
9. Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome. Nature: 2012; 486 207 214
10. Zhu B., Wang X., Li L. Human gut microbiome: the second genome of human body. Protein Cell: 2010; 1 718 725
11. Shanahan F. The gut microbiota - a clinical perspective on lessons learned. Nat Rev Gastroenterol Hepatol: 2012; 9 609 614
12. Lepage P., Leclerc M. C., Joossens M. et al. A metagenomic insight into our gut's microbiome. Gut: 2013; 62 146 158
13. Eckburg P. B., Bik E. M., Bernstein C. N. et al. Diversity of the human intestinal microbial flora. Science: 2005; 308 1635 1638
14. Costello E. K., Lauber C. L., Hamady M. et al. Bacterial community variation in human body habitats across space and time. Science: 2009; 326 1694 1697
15. Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature: 2010; 464 59 65
16. Lee Y. K., Mazmanian S. K. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science: 2010; 330 1768 1773
17. Backhed F., Manchester J. K., Semenkovich C. F. et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A: 2007; 104 979 984
18. Turnbaugh P. J., Ley R. E., Mahowald M. A. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature: 2006; 444 1027 1031
19. Ley R. E., Backhed F., Turnbaugh P. et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A: 2005; 102 11070 11075
20. Ley R. E., Turnbaugh P. J., Klein S. et al. Microbial ecology: human gut microbes associated with obesity. Nature: 2006; 444 1022 1023
21. Backhed F., Ding H., Wang T. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A: 2004; 101 15718 15723
22. Vrieze A., Van Nood E., Holleman F. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology: 2012; 143 913 916
23. Van Nood E., Vrieze A., Nieuwdorp M. et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med: 2013; 368 407 415
24. Smits L. P., Bouter K. E., de Vos W. M. et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology: 2013; 145 946 953
25. Kootte R. S., Vrieze A., Holleman F. et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab: 2012; 14 112 120
26. Karlsson F. H., Tremaroli V., Nookaew I. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature: 2013; 498 99 103
27. Qin J., Li Y., Cai Z. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature: 2012; 490 55 60
28. Larsen N., Vogensen F. K., van den Berg F. W. et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One: 2010; 5 e9085
29. Shin N. R., Lee J. C., Lee H. Y. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut: 2014; 63 727 735
30. Olle B. Medicines from microbiota. Nat Biotechnol: 2013; 31 309 315
31. de Vos W. M., Nieuwdorp M. Genomics: A gut prediction. Nature: 2013; 498 48 49
32. Cani P. D., Delzenne N. M. The gut microbiome as therapeutic target. Pharmacol Ther: 2011; 130 202 212
33. Flint H. J., Bayer E. A., Rincon M. T. et al. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol: 2008; 6 121 131
34. Robertson M. D., Bickerton A. S., Dennis A. L. et al. Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr: 2005; 82 559 567
35. Robertson M. D., Currie J. M., Morgan L. M. et al. Prior short-term consumption of resistant starch enhances postprandial insulin sensitivity in healthy subjects. Diabetologia: 2003; 46 659 665
36. Mendeloff A. I. Dietary fiber and human health. N Engl J Med: 1977; 297 811 814
37. Elamin E. E., Masclee A. A., Dekker J. et al. Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. J Nutr: 2013; 143 1872 1881
38. Ma X., Fan P. X., Li L. S. et al. Butyrate promotes the recovering of intestinal wound healing through its positive effect on the tight junctions. J Anim Sci: 2012; 90 04 266 268
39. Wellen K. E., Hotamisligil G. S. Inflammation, stress, and diabetes. J Clin Invest: 2005; 115 1111 1119
40. Hotamisligil G. S. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord: 2003; 27 03 S53 S55
41. Cani P. D., Amar J., Iglesias M. A. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes: 2007; 56 1761 1772
42. Cani P. D., Possemiers S., Van de Wiele T. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut: 2009; 58 1091 1103
43. Mithieux G. The new functions of the gut in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care: 2005; 8 445 449
44. Mithieux G., Misery P., Magnan C. et al. Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab: 2005; 2 321 329
45. Delaere F., Duchampt A., Mounien L. et al. The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing. Mol Metab: 2012; 2 47 53
46. De Vadder F., Kovatcheva-Datchary P., Goncalves D. et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell: 2014; 156 84 96
47. Brown A. J., Goldsworthy S. M., Barnes A. A. et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem: 2003; 278 11312 11319
48. Le Poul E., Loison C., Struyf S. et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem: 2003; 278 25481 25489
49. Kimura I., Ozawa K., Inoue D. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun: 2013; 4 1829
50. Tolhurst G., Heffron H., Lam Y. S. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes: 2012; 61 364 371
51. Mithieux G., Gautier-Stein A. Intestinal glucose metabolism revisited. Diabetes Res Clin Pract: 2014; 105 295 301
52. Tazoe H., Otomo Y., Kaji I. et al. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol: 2008; 59 02 251 262
53. Samuel B. S., Shaito A., Motoike T. et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A: 2008; 105 16767 16772
54. Hirasawa A., Tsumaya K., Awaji T. et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med: 2005; 11 90 94
55. Ichimura A., Hirasawa A., Poulain-Godefroy O. et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature: 2012; 483 350 354
56. Gao Z., Yin J., Zhang J. et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes: 2009; 58 1509 1517
57. Cani P. D., Neyrinck A. M., Fava F. et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia: 2007; 50 2374 2383
58. Cani P. D., Osto M., Geurts L. et al. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes: 2012; 3 279 288
59. Cotillard A., Kennedy S. P., Kong L. C. et al. Dietary intervention impact on gut microbial gene richness. Nature: 2013; 500 585 588